CyanVac LLC is set to begin a federally funded Phase 2b trial this fall for its intranasal COVID-19 vaccine, CVXGA, comparing it to an mRNA vaccine in 10,000 participants. Developed at the University of Georgia, the vaccine utilizes a unique delivery platform and aims for enhanced long-term protection against the virus. University of Georgia-based startup CyanVac LLC has received federal funding to conduct a Phase 2b clinical trial to compare its intranasal vaccine candidates, CVXGA, which are designed to provide protection against COVID-19 .
As part of the award from Project NextGen, a federal initiative based in the U.S. Department of Health and Human Services (HHS), CyanVac will sponsor a randomized, double-blind Phase 2b study with 10,000 participants to compare the efficacy and safety of the intranasal vaccine against an FDA-approved mRNA-based COVID-19 vaccine.
The new vaccine is based on a viral delivery platform developed by He containing modified strains of parainfluenza virus 5, which causes kennel cough in dogs but is harmless to humans. CyanVac’s Commitment and Project Goals CyanVac was founded by Biao He, Regents’ Entrepreneur, Fred C. Davison Distinguished University Chair in Veterinary Medicine and a faculty member in UGA’s College of Veterinary Medicine (CVM).
He served on a White House panel to advise on the future of COVID-19 vaccines and was named both UGA Inventor and Entrepreneur of the Year. Biao He in his laboratory. Credit: Andrew Davis Tuckert �.
